Viral vectors and their use in therapeutic methods
US-9555072-B2 · Jan 31, 2017 · US
Viral vectors and their use in therapeutic methods
US10532095B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10532095-B2 |
| Application number | US-201615383578-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 19, 2016 |
| Priority date | Mar 27, 2001 |
| Publication date | Jan 14, 2020 |
| Grant date | Jan 14, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inducing a systemic immune response to hepatoma in a patient, said method comprising administering to said patient a herpes simplex virus-1 (HSV-1) comprising: an inactivating mutation in the ICP47 locus of said herpes virus wherein said inactivating mutation occurs between the BstEII site and the EcoNI site of the BamHI fragment encompassing the ICP47 region, and said mutation places US11 under the control of the ICP47 immediate-early promoter that results in early expression of US11; an inactivating mutation in the γ34.5 neurovirulence locus of said virus; and an inactivating mutation in the ICP6 locus of said virus. 2. The method of claim 1 , wherein said herpes virus is administered to a tumor of said patient. 3. The method of claim 1 , wherein said patient has or is at risk of developing metastatic cancer. 4. The method of claim 1 , wherein the HSV-1 further comprises sequences encoding a heterologous gene product. 5. The method of claim 4 , wherein said heterologous gene product comprises a vaccine antigen or an immunomodulatory protein. 6. A method of treating a hepatoma in a patient, said method comprising administering to said patient a herpes simplex virus-1 (HSV-1) comprising: an inactivating mutation in the ICP47 locus of said herpes virus wherein said inactivating mutation occurs between the BstEII site and the EcoNI site of the BamHI fragment encompassing the ICP47 region, and said mutation places US11 under the control of the ICP47 immediate-early promoter that results in early expression of US11; an inactivating mutation in the γ34.5 neurovirulence locus of said virus; and an inactivating mutation in the ICP6 locus of said virus. 7. The method of claim 6 , wherein said herpes virus is administered to a tumor of said patient. 8. The method of claim 6 , wherein said patient has or is at risk of developing metastatic cancer. 9. The method of claim 6 , wherein the HSV-1 further comprises sequences encoding a heterologous gene product. 10. The method of claim 9 , wherein said heterologous gene product comprises a vaccine antigen or an immunomodulatory protein.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10532095B2 cover?
- The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
- Who is the assignee on this patent?
- Massachusetts Gen Hospital, Univ Georgetown, Catherex Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/245. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).